Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations.

摘要: Abstract This article summarizes recent American Brachytherapy Society (ABS) recommendations for permanent prostate brachytherapy. The ABS recommends treating patients with high probability of organ-confined disease brachytherapy alone. candidates a significant risk extraprostatic extension should be treated supplemental external beam radiation therapy (EBRT). recommended prescription doses monotherapy are 145 Gy (125)I and 125 (103)Pd. corresponding boost (after 40 to 50 EBRT) 110 100 Gy, respectively. that post-implant dosimetry performed on all undergoing optimal patient care. A dose-volume histogram (DVH) the D(90) (dose 90% gland) reported by centers. Additionally, D(80) D(100), fractional V(80), V(90), V(100), V(150), V(200) (ie, percentage volume receiving 80%, 90%, 100%, 150%, 200% prescribed dose, respectively), rectal urethral ultimately correlated clinical outcome in research environment. On-line, real-time dosimetry, effects dose heterogeneity, tissue heterogeneity need further investigation.